Erlotinib

Generic Name: Erlotinib

Brand Names: Tarceva

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃N_₃O_₄

CAS Number: 183321-74-6

Unique Ingredient Identifier: J4T82NDH7E

Background: Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.

Indication: Erlotinib is indicated for:

The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.

Associated Conditions: Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer

Clinical Trials

A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Erlotinib
Drug: Pertuzumab

First Posted Date: 2015-07-23

Last Posted Date: 2015-10-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 17

Registration Number: NCT02507375

A Study of ASP2215 in Combination With Erlotinib in Subjects With Epidermal Growth Factor Receptor (EGFR) Activating Mutation-Positive (EGFRm+) Advanced Non-Small-Cell Lung Cancer (NSCLC) Who Have Acquired Resistance to an EGFR Tyrosine Kinase Inhibitor (TKI)

Phase 1

Terminated

Conditions: Non-Small-Cell Lung Cancer

Interventions: Drug: Gilteritinib
Drug: Erlotinib

First Posted Date: 2015-07-13

Last Posted Date: 2024-11-27

Lead Sponsor: Astellas Pharma Global Development, Inc.

Target Recruit Count: 10

Registration Number: NCT02495233

Locations: 🇯🇵
Site JP81005, Osakasayama, Osaka, Japan
🇯🇵
Site JP81004, Fukuoka Minami-ku, Fukuoka, Japan
🇯🇵
Site JP81003, Suntogun Nagaizumicho,Shizuoka, Japan

and more 1 locations

An Extension Study of Onartuzumab in Participants With Solid Tumors on Study Treatment Previously Enrolled in a Company Sponsored Study

Phase 3

Completed

Conditions: Solid Tumor

Interventions: Drug: Onartuzumab
Drug: Bevacizumab
Drug: Erlotinib

First Posted Date: 2015-07-02

Last Posted Date: 2019-07-23

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 12

Registration Number: NCT02488330

Locations: 🇫🇷
Hopital Roger Salengro, Lille, France
🇯🇵
National Hospital Organization Shikoku Cancer Center, Ehime, Japan
🇮🇹
Azienda Ospedaliero Universitaria San Giovanni Battista Di Torino, Torino, Piemonte, Italy

and more 7 locations

A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification

Phase 1

Terminated

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: INC280 single agent
Drug: erlotinib

First Posted Date: 2015-06-11

Last Posted Date: 2020-02-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT02468661

Locations: 🇺🇸
Henry Ford Hospital SC, Detroit, Michigan, United States
🇺🇸
Los Angeles Hematology/Oncology Medical Group, Los Angeles, California, United States
🇺🇸
University of California Irvine Medical Center Chao Family SC, Orange, California, United States

and more 4 locations

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Not Applicable

Completed

Conditions: Oligometastatic Lung Adenocarcinoma

Interventions: Drug: Erlotinib
Other: Local Therapies

First Posted Date: 2015-05-21

Last Posted Date: 2018-05-21

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT02450591

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering at Mercy Medical Center, Rockville Centre, New York, United States
🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States

and more 4 locations

A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer

Phase 1

Completed

Conditions: Non-Small Cell Lung Cancer

Interventions: Drug: Bemcentinib
Drug: Erlotinib

First Posted Date: 2015-04-23

Last Posted Date: 2025-02-26

Lead Sponsor: BerGenBio ASA

Target Recruit Count: 40

Registration Number: NCT02424617

Locations: 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

and more 7 locations

A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)

Phase 3

Active, not recruiting

Conditions: Metastatic Non-Small Cell Lung Cancer

Interventions: Drug: Placebo
Drug: Ramucirumab
Drug: Erlotinib
Drug: Gefitinib
Drug: Osimertinib

First Posted Date: 2015-04-08

Last Posted Date: 2025-04-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 545

Registration Number: NCT02411448

Locations: 🇺🇸
UCLA Hematology/Oncology - Santa Monica, Los Angeles, California, United States
🇺🇸
AHN Allegheny General Hospital, Pittsburgh, Pennsylvania, United States
🇯🇵
Hyogo Prefectual Amagasaki General Medical Center, Amagashiki, Hyogo, Japan

and more 103 locations